Drugs and fracture repair.
Aspenberg
Per
P
Department of Neuroscience and Locomotion, Faculty of Health Science, Orthopaedics and Sports Medicine, Linköping, SE-581 85, Sweden. per.aspenberg@inr.liu.se
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology; D017102:Fracture Healing / Q000187:drug effects*; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects*; D010281:Parathyroid Hormone / Q000494:pharmacology; D011982:Receptors, Prostaglandin / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D000924:Anticholesteremic Agents; D000925:Anticoagulants; D000970:Antineoplastic Agents; D019485:Bone Morphogenetic Proteins; D016861:Cyclooxygenase Inhibitors; D005343:Fibrinolytic Agents; D006133:Growth Substances; D010281:Parathyroid Hormone; D011982:Receptors, Prostaglandin